NCT06483334

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: ACTIVE_NOT_RECRUITING

Phase: PHASE1, PHASE2

Sponsor: Merck Sharp & Dohme LLC

Condition: Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma

Signal summary

Status signal: Low Signal

Timeline signals: long_recruitment_duration_signal

Results signal: Low Signal

Operational burden: strict_eligibility_signal

Stopped reason

No stop reason available in the current public record.